Eli Lilly’s triple agonist retatrutide hits 28.3% mean weight loss in TRIUMPH-1 phase 3, blowing past tirzepatide benchmarks & rewriting obesity math for payers, PBMs & the Lilly Novo Duopoly
Video Preview
🎧 Podcast episode for paid subscribers only. Also available on Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of Contents
What TRIUMPH-1 actually delivered
Why glucagon agonism rewires the math
How retatrutide stacks up against tirzepatide and semaglutide
The 104 week extension and the bariatric surgery threshold question
Cardiometabolic signals beyond the scale
The 4 mg dose as a separate strategic asset
Payer and PBM implications
The LLY NVO duopoly and the oral pipeline question
Manufacturing, pricing, and the MFN policy overlay
What to watch from here
Topline data points from the May 21, 2026 readout:
TRIUMPH-1 = phase 3 of retatrutide (GIP, GLP-1, glucagon triple agonist) in adults with obesity or overweight + ≥1 weight-related comorbidity, no T2D
Baseline: 112.7 kg (248.5 lbs), BMI 40.0
80 wk primary endpoint, percent body weight change:
4 mg: -19.0% (-47.2 lbs)
9 mg: -25.9% (-64.4 lbs)
12 mg: -28.3% (-70.3 lbs)
Placebo: -2.2% (-5.5 lbs)
Categorical responders at 12 mg: 62.5% hit ≥25% TWL, 45.3% hit ≥30%, 27.2% hit ≥35%
65.3% of 12 mg arm crossed back under BMI 30 at wk 80; 37.5% of class 3 obesity entrants exited clinical obesity entirely
Waist circumference reduction: -24.1 cm at 12 mg vs -3.6 cm placebo
104 wk extension (n=532, BMI ≥35 baseline 121.7 kg, BMI 42.8):
12 mg to MTD: -30.3% (-85.0 lbs)
9 mg to MTD: -29.5% (-80.7 lbs)
4 mg to MTD: -27.9% (-73.3 lbs)
Placebo to MTD: -19.2% (-49.9 lbs)
Cardiometabolic improvements vs placebo: waist circumference, non-HDL cholesterol, triglycerides, systolic BP, hsCRP
4 mg dose: AE-driven discontinuation rate lower than placebo
Strategic takeaways:
First triple agonist past phase 3, ahead of every competing program
TWL distribution closes gap with bariatric surgery (Roux-en-Y ~30%, sleeve ~25%)
Pressure on bariatric procedure volumes, PBM utilization management regimes, ICER cost-effectiveness models
LLY widens lead over NVO further; CagriSema and amycretin look pedestrian in comparison
Open questions: pricing under MFN regime, Medicare Part D coverage path via outcomes trial, manufacturing capacity, orforglipron positioning in the same portfolio
What TRIUMPH-1 actually delivered
The trial put retatrutide up against placebo at three doses (4 mg, 9 mg, 12 mg) in adults carrying obesity or overweight plus at least one weight-related comorbidity, with type 2 diabetes pulled out of enrollment to keep the obesity question clean. Baseline cohort sat at 112.7 kg (248.5 lbs) with a mean BMI of 40.0, which is solidly class 3 territory and a much heavier starting point than the SURMOUNT-1 cohort that anchored tirzepatide’s label. At 80 weeks the 12 mg arm dropped 28.3 percent of body weight on average, which works out to 70.3 lbs off a 248.5 lb starting point. The 9 mg arm landed at 25.9 percent (64.4 lbs). The 4 mg arm, reached with a single escalation step, came in at 19.0 percent (47.2 lbs). Placebo did what placebo does in obesity trials, which is essentially nothing, posting 2.2 percent (5.5 lbs).
The categorical responder numbers are arguably more interesting than the mean. At the 12 mg dose, 62.5 percent of participants hit at least 25 percent weight reduction, 45.3 percent crossed 30 percent, and 27.2 percent crossed 35 percent. For reference, the 35 percent threshold has historically been the exclusive turf of bariatric surgery, and it was hit by basically no one on placebo (0.3 percent, which is statistical noise). The 65.3 percent figure for participants who crossed back under the BMI 30 threshold at week 80 is the line that the press release is going to get quoted on, because crossing out of clinical obesity is the kind of headline number that translates cleanly into payer reimbursement debates and clinical guideline updates. The 37.5 percent figure for class 3 obesity entrants who exited clinical obesity entirely is the more remarkable subset result, because those are the patients with the most metabolic burden and the most baseline weight to shed, and the historical pharmacological track record on that population has been close to nil.
Why glucagon agonism rewires the math
